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Abstract
Curcumin has attracted great attention in the therapeutic arsenal in clinical oncology due to its chemopreventive,
antitumoral, radiosensibilizing and chemosensibilizing activities against various types of aggressive and recurrent
cancers. These malignancies include leukemias, lymphomas, multiple myeloma, brain cancer, melanoma and skin,
lung, prostate, breast, ovarian, liver, gastrointestinal, pancreatic and colorectal epithelial cancers. Curcumin mediates
its anti-proliferative, anti-invasive and apoptotic effects on cancer cells, including cancer stem/progenitor cells and
their progenies, through multiple molecular mechanisms. The oncogenic pathways inhibited by curcumin
encompass the members of epidermal growth factor receptors (EGFR and erbB2), sonic hedgehog (SHH)/GLIs and
Wnt/b-catenin and downstream signaling elements such as Akt, nuclear factor-kappa B (NF-B) and signal
transducers and activators of transcription (STATs). In counterbalance, the high metabolic instability and poor
systemic bioavailability of curcumin limit its therapeutic efficacy in human. Of great therapeutic interest, the
selective delivery of synthetic analogs or nanotechnology-based formulations of curcumin to tumors, alone or in
combination with other anticancer drugs, may improve their chemopreventive and chemotherapeutic efficacies
against cancer progression and relapse. Novel curcumin formulations may also be used to reverse drug resistance,
eradicate the total cancer cell mass and improve the anticarcinogenic efficacy of the current anti-hormonal and
chemotherapeutic treatments for patients with various aggressive and lethal cancers.
Background
The deregulation and sustained activation of multiple
tumorigenic pathways are typically implicated in cancer
development and progression to locally advanced,
aggressive and metastatic stages as well as in treatment
resistance and disease relapse [1-5]. Consequently, the
use of therapeutic agents acting on different deregulated
gene products, alone or in combination therapy, may
represent a potentially better strategy than the targeting
of one specific oncogenic product to overcome treat-
ment resistance and prevent cancer development and
disease recurrence [1-5]. The non-toxic substance cur-
cumin is the major bioactive ingredient extracted from
the rhizome of the plant Curcuma longa Linn,a l s oa s
known as turmeric [6,7]. Curcumin has been used as a
dietary supplement as well as a therapeutic agent in
Chinese medicine and other Asian medicines for centu-
ries [6,7]. Recently, curcumin, which is a polyphenolic
compound, has emerged worldwide as a potent thera-
peutic substance for treating diverse human diseases.
Curcumin displays a wide range of pharmacological
properties against various human disorders, such as
metabolic and infectious diseases, diabetes, psoriasis,
rheumatoid arthritis, atherosclerosis, Parkinson’sa n d
Alzheimer’s diseases and cancer [6-14].
In vitro and in vivo studies have indicated that curcumin
induces chemopreventive and chemotherapeutic effects
against various types of human cancers. More specifically,
curcumin exhibits anticarcinogenic effects on leukemias,
lymphomas, multiple myeloma, brain cancer and mela-
noma as well as skin, cervix, lung, prostate, breast, ovarian,
bladder, liver, gastrointestinal tract, pancreatic and color-
ectal epithelial cancers [2,9,15-36]. Curcumin displays
strong anti-inflammatory, antioxidant, anti-aging, chemo-
preventive, antitumoral, anti-angiogenic, anti-metastatic,
radiosensitizing and chemosensitizing effects in cancer
* Correspondence: mmimeault@unmc.edu; sbatra@unmc.edu
Department of Biochemistry and Molecular Biology, College of Medicine,
Eppley Institute for Research in Cancer and Allied Diseases, University of
Nebraska Medical Center, Omaha, NE 68198-5870, USA
Mimeault and Batra Chinese Medicine 2011, 6:31
http://www.cmjournal.org/content/6/1/31
© 2011 Mimeault and Batra; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.cells in a concentration- and cell type-dependent manner
(Figures 1 and 2) [2,7,9,10,22,37-39]. Of therapeutic inter-
est, studies have indicated that curcumin as a single agent
is safe and exhibits no major toxicity and only protects
normal cells and organs at least in part by up-regulating
the nuclear factor erythroid-derived-2 related factor 2
(Nrf2)-induced antioxidant gene products [8,38,40-46].
The anticarcinogenic effects induced by curcumin in can-
cer cells are mediated via the modulation of multiple
oncogenic signaling transduction elements. Potential
mechanisms of anticarcinogenic effects induced by curcu-
min in cancer cells include the down-regulation of the epi-
dermal growth factor receptor (EGFR) family members
(EGFR/erbB1 and erbB2/HER2), insulin-like growth factor
type-1 receptor (IGF-1R), sonic hedgehog (SHH/GLIs)
and Wnt/b-catenin and their downstream signaling effec-
tors (Figures 1 and 2). The intracellular signaling
transduction elements inhibited by curcumin include the
signal transducers and activators of transcription (STATs),
c-jun/activator protein-1 (AP-1), phosphatidylinositol-3’-
kinase (PI3K)/Akt, nuclear factor-kappaB (NF-B) and its
targeted genes such as interleukin-6 (IL-6), cyclooxygen-
ase-2 (COX-2) and matrix metalloproteinases (MMPs)
(Figures 1 and 2) [2,9,17-21,24-30,47,48]. Other signaling
components modulated through curcumin include the up-
regulation of p21
WAP1 and p27
KIP1 cyclin-dependent
kinase inhibitors and down-regulation of Bcl-2, Bcl-xL,
survivin, induced myeloid leukemia cell differentiation
protein-1 (Mcl-1) and glyoxalase 1 as well as the activation
of Bax, Bad and caspase cascade-induced apoptosis (Fig-
ures 1 and 2) [2,9,15,17-21,24].
In addition, some pre-clinical investigations have
revealed that the administration of curcumin in the diet,
alone or in combination with current therapeutic
Figure 1 Tumorigenic cascades initiated by different growth factors in cancer cells and the anticarcinogenic effects induced by
dietary curcumin on the transduction signaling elements. The inhibitory effect of curcumin on the expression and/or activity of EGFR, erbB2,
IGF-1R, and their downstream signaling elements, sonic hedgehog (SHH/SMO/GLIs), Wnt/b-catenin and ATP-binding cassette multidrug
transporters such as ABCG2 in cancer cells are indicated. Moreover, the enhanced expression of p21
WAP1 and p27
KIP1 cyclin-dependent kinase
inhibitors and inhibition of mitotic effects induced by curcumin resulting in a cell cycle arrest and reduced expression levels of different gene
products involved in the growth, invasion and metastasis of cancer cells as well as the activation by curcumin of mitochondrial factors and
caspase pathway-induced apoptosis are also indicated. In addition, the scheme also shows novel nanotechnology-based curcumin delivery
systems consisting of using either a poly(b-cyclodextrin)-curcumin complex formulation, or a polymeric micelle-encapsulated curcumin labeled
with a ligand or monoclonal antibody (mAb) that specifically interacts with a receptor expressing by cancer cells for the selective targeting of
curcumin are also illustrated.
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ment and progression to locally invasive and metastatic
stages in animal models in vivo [2,16,34,49-54]. Impor-
tantly, curcumin and its derivatives can also inhibit pro-
liferation and induce apoptosis on multidrug resistant
cancer cells (eg cancer stem/progenitor cells with stem
cell-like properties) by modulating the expression and/
or activity of distinct survival pathways, ATP-binding
cassette (ABC) multidrug transporters and micro RNAs
(Figures 1 and 2) [15,55-70]. The data from trials with
patients have also corroborated the safety profile and
chemopreventive and chemotherapeutic effects of curcu-
min against diverse diseases and aggressive cancers in
the clinical settings [9,37,69,71-81]. However, the thera-
peutic applications of curcumin in human are limited by
its high metabolic instability as well as poor absorption
and bioavailability. Synthetic analogs and formulations
of curcumin have been developed, including its com-
plexation with polymeric micelles or nanoparticle-based
encapsulation that exhibit greater chemical stability,
systemic bioavailability and antitumoral activities than
naturally occurring curcumin (Figures 1 and 3)
[7,24,82-101].
In this article, we review the most recent advances on
the pharmacological characterization of the anticarcino-
genic properties of curcumina n di t sn o v e ls y n t h e t i c
analogs and nanotechnology-based formulations as well
as the molecular mechanisms at the basis of the
observed therapeutic effects induced by these agents.
Search strategy
Literature search for this article was conducted in the
MEDLINE/PubMed central database covering January
2000 to May 2011, with the term ‘curcumin’ alone and
combined with other keywords including ‘dietary
agents’, ‘cancer’, ‘prostate cancer’, ‘brain cancer’, ‘pan-
creatic cancer’, ‘colorectal cancer’, ‘cancer stem cells’,
‘cancer prevention’, ‘cancer therapy’, ‘chemotherapy’,
‘structure-activity study’, ‘curcumin analogues’and ‘cur-
cumin formulation and nanotechnology’.M o r e o v e r ,t h e
Figure 2 Potential growth factor pathways, intracellular signal components and drug resistance-associated molecules modulated by
curcumin involved in its chemopreventive and chemotherapeutic effects on cancer cells. The scheme shows the inhibitory effects
induced by curcumin on distinct oncogenic growth factor cascades and their multiple downstream intracellular signaling elements and ABC-
multidrug transporters in cancer cells involved in the mediation of its cancer preventive and anticarcinogenic properties.
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sites, namely http://www.google.com and http://www.
clinicaltrials.gov. The relevant papers on chemopreven-
tive and chemotherapeutic effects induced by curcumin
or its derivatives, alone or in combination therapy, with
an emphasis on brain, prostate, pancreatic and colorec-
tal cancers were included in the review.
Potential applications of curcumin in cancer prevention
and therapy
Curcumin exhibits in vitro and in vivo chemopreventive
and chemotherapeutic effects on various cancer cell types
and animal models [2,7,16,26,34,50-54,102-114]. For
instance, curcumin in the diet has been shown to prevent
or counteract the inflammation- and carcinogen-promoted
tumorigenesis in vivo in mouse models [16,49,50,
53,112,114]. More specifically, it has been reported that
curcumin triggered the apoptosis on the murine K-Ras-
induced lung adenocarcinoma cell line (LLR-10 and LKR-
13) [112]. Moreover, 1% curcumin in the diet suppressed
the non-typeable Hemophilius influenzae (NTHi)-induced
chronic airway inflammation and lung cancer progression
in mice through anti-inflammatory and anti-tumoral
effects [112]. In the same manner, a topical application of
curcumin also prevented the formation of benzo[a]pyrene-
DNA adducts and its tumorigenic activity in epidermis in
CD-1 mice [49]. A topical application of curcumin was
also effective at inhibiting the skin tumor promotion
mediated by 12-O-tetradecanoylphorbol-13-acetate (TPA)
in 7,12-dimethylbenz[a]anthracene-initiated mouse skin
Figure 3 Chemical structures of naturally occurring curcumin and its novel synthetic analogs. The scheme shows (A) The diketone and
keto-enol forms of curcumin. Curcumin exists as an equilibrium mixture of two tautomeric forms in solution. The enol structure of curcumin,
which is stabilized by intramolecular H-bonding, is the most energetically stabilized and favored form; (B) chemical structures of novel synthetic
analogs of dietary curcumin (dimethoxycurcumin, GO-Y039, EF24, compound 23 and difluorinated-curcumin “CDF”) showing improved chemical
stability and anticarcinogenic properties on different cancer cell lines.
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0.5-2.0% commercial grade curcumin (77% curcumin, 17%
demethoxycurcumin and 3% bisdemethoxycurcumin) in
the diet inhibited benzo(a)pyrene-induced forestomach
tumorigenesis in A/J mice, N-ethyl-N’-nitro-N-nitrosogua-
nidine-induced duodenal tumorigenesis in C57BL/6 mice
and azoxymethane (AOM)-induced colon tumorigenesis
in CF-1 mice or F344 rats [16,53].
In addition, curcumin has also been shown to sup-
press proliferation while it induced apoptosis and radio-
sensibilizing and chemosensibilizing effects on diverse
human cancer cell types, including leukemia and lym-
phoma cells, multiple myeloma cells and brain, mela-
noma and epithelial cancer cells (Figures 1 and 2)
[17,25,26,34,39,102,110,115-118]. The cytotoxic effects
of curcumin were mediated by down-regulating the sus-
tained activation of PI3K/Akt and/or IBa kinase
(IBaK) and nuclear translocation of NF-B and STATs
induced by growth factors (Figures 1 and 2)
[17,25,26,34,39,102,110,115-118]. For instance, it has
been observed that curcumin down-regulated the consti-
tutive activation of IBa kinase-induced NF-B and the
expression of these target genes, including IL-6, cyclin
D1, Bcl-2 and Bcl-xL in human multiple myeloma cells
[26]. The curcumin treatment of multiple myeloma cells
was also effective at suppressing the proliferation, indu-
cing apoptosis and improving the sensitivity of these
cancer cells to the cytotoxic effects induced by che-
motherapeutic drugs, vincristine and melphalan [26].
Moreover, curcumin induced antiproliferative and apop-
totic effects on human A375, C32, G-361 and WM 266
melanoma cell lines, all of which have B-Raf mutations,
B16-R melanoma cells resistant to doxorubicin and
novel mouse melanoma cells, whereas curcumin induced
no cytotoxic effect on normal melanocytes [33,119-122].
The cytotoxic effects of curcumin on these melanoma
cell lines were mediated in part through the down-regu-
lation of the constitutive activation of IBa kinase-
induced NF-B in a manner independent of the B-Raf/
MEK/ERK and Akt pathways [33,119-122]. It has been
noticed that a combination of low doses of curcumin
plus tamoxifen resulted in a synergistic induction of
apoptosis and autophagy in chemoresistant melanoma
cells and the silencing of multidrug resistance transpor-
ter ABCA1 in highly tumorigenic and metastatic human
M14 melanoma cells, which are resistant to curcumin
treatment, restored their sensibility to curcumin
[122,123]. Importantly, the results from in vivo studies
consisting of the intraperitoneal injection of curcumin at
doses of 50 and 100 mg/kg every 2 days, respectively
have also indicated that this dietary compound inhibited
the tumor growth and spontaneous metastasis of
B16BL6 melanoma cells in mice at least in part by
down-regulating the expression at the transcriptional
level of an oncogenic product, phosphatase of regenerat-
ing liver-3 (PRL-3) [34]. Furthermore, curcumin also
reduced the invasion and strongly induced apoptosis in
the human estrogen receptor-a (ER-a)-negative and
aggressive MDA-MB-231 breast cancer cell line in vitro
concomitant with a down-regulation of the NF-Bs u r -
vival pathway and expression levels of inflammatory
cytokines CXCL1 and CXCL2, CXCR4 and MMP
[35,36]. Moreover, 1% curcumin in the diet decreased
the incidence of lung metastases derived from MDA-
MB-231 cells injected into the heart of immunodeficient
mice [36].
Importantly, despite the fact that curcumin may act as
a cytotoxic, chemosensitizing and radiosensitizing agent
in cancer cells, it can also protect normal cells and
organs such as brain, intestine, liver, kidney, oral
mucosa, heart and spleen against oxidative stress and
chemotherapy- and radiotherapy-induced toxicity
[38,40-46,73,124]. The protective effects of curcumin
appear to be mediated through its ability to directly sca-
venge free radicals or indirectly by up-regulating the
endogenous cellular antioxidant mechanisms including
the activation of cytoprotective Nrf2-induced target
genes [8,38,40-46,124]. In fact, Nrf2 acts as a transcrip-
tional activator of the antioxidant responsive element
(ARE)-mediated gene expression, including phase II
detoxification and antioxidant stress enzymes such as
hemeoxygenase-1, glutathione peroxidase, modulatory
subunit of gamma-glutamyl-cysteine ligase, which is
involved in glutathione synthesis, and NAD(P)H:quinone
oxidoreductase 1 [38,40-46]. Thus, the modulation of
these gene products by curcumin may contribute in part
to its antioxidant and cytoprotectrive effects in normal
cells including its neuroprotective activity [38,40-46].
Together, these observations suggest that curcumin
may counteract the development of a variety of cancers
and overcome resistance to current radiotherapy and
chemotherapy that may be promoted by oxidative stress
and sustained activation of the survival pathways such
as Akt and NF-B without major toxicity on normal
cells (Figures 1 and 2). We report in a more detailed
manner the recent advances on in vitro and in vivo stu-
dies of the chemopreventive and chemotherapeutic
effects of curcumin that have been performed on brain,
prostate, pancreatic and colorectal cancers as well as the
characterization of the pharmacological properties of
novel curcumin analogs and formulations with improved
chemical stability and anticarcinogenic properties.
Brain cancer
Medulloblastomas and malignant gliomas are among the
most aggressive primary brain tumors that frequently
occur in children and adults respectively [125-128].
Importantly, curcumin has been shown to suppress the
proliferation, trigger cell cycle arrest at the G2/M phase
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cells in vitro a n di na na n i m a lm o d e lin vivo [129-140].
More specifically, curcumin induced the anti-prolifera-
tive, anti-migratory and apoptotic effects on medullo-
blastoma cells via the down-regulation of the expression
levels of the SHH ligand and the GLI-1 transcriptional
effector of the hedgehog cascade, b-catenin, the phos-
phorylated forms of Akt and NF-Ba sw e l la st h e i r
downstream targets such as c-Myc, N-Myc, cyclin D1
and anti-apoptotic factors Bcl-2 and Bcl-xL (Figures 1
and 2) [129,130]. It has been noticed that the curcumin-
resistant medulloblastoma cells, which exhibited no
decrease in the levels of SHH and Bcl-2 levels could be
sensitized to curcumin by a co-treatment with SMO
antagonist, cyclopamine [129]. The apoptotic effect of
curcumin was also enhanced by another dietary sub-
stance, namely piperine, the main alkaloid from black
pepper that acts as an enhancer of curcumin bioavail-
ability in humans [129]. Moreover, curcumin was also
effective at improving the cytotoxic effects induced by
cisplatin and g-rays via the down-regulation of the anti-
apoptotic factor Bcl-2 in medulloblastoma cells [129].
In addition, several studies have indicated that curcu-
min can induce the antiproliferative, apoptotic, radiosen-
sibilizing and chemosensibilizing effects on glioma cells
via the up-regulation of p53, p21
WAF1 and the inhibitor
of growth 4 (ING4), inhibition of NF-B and AP-1 tran-
scriptional activities and stimulation of the caspase cas-
cade [132-135,138-140]. For instance, curcumin induced
a histone hypoacetylation in glioma cells and apoptotic
cell death through a poly (ADP-ribose) polymerase
(PARP)- and caspase 3-mediated pathway while it pro-
moted the neurogenesis in neural progenitor cells (Fig-
ure 1) [132]. Moreover, curcumin was also effective at
attenuating the cell viability of human (T98G, U87MG
and T67) and rat C6 glioma cell lines via the inhibition
of Akt/NF-B and c-Jun N-terminal kinase (JNK)/AP-1
signaling pathways [133]. Of clinical interest, curcumin
has also been observed to sensitize glioma cells to radia-
tion and several current chemotherapeutic drugs,
including cisplatin, etoposide, camptothecin and doxoru-
bicin through a reduced expression of Bcl-2 and the
inhibitor of apoptosis proteins (IAPs) as well as DNA
repair enzymes such as O6-methylguanine-DNA methyl-
transferase (MGMT), DNA-dependent protein kinase,
Ku70, Ku80 and excision repair cross-complementing
rodent repair deficiency, complementation group 1
(ERCC-1) [133].
Together, these results suggest that curcumin or its deri-
vatives could be used as adjuvant treatment for improving
the anticarcinogenic efficacy of current radiation therapy
and chemotherapy against locally advanced, disseminated
and recurrent medulloblastomas and gliomas, which retain
lethal with the current treatment options.
Prostate cancer
Accumulating experimental lines of evidence have indi-
cated that curcumin is effective in counteracting pros-
tate cancer initiation and progression to locally invasive,
androgen-independent (AI) and metastatic disease stages
[7,16,51,103-109,141]. It has been shown that curcumin
can induce the antiproliferative, anti-invasive, antiangio-
genic and apoptotic effects on human AI PcBra1 cells
from localized prostate cancer and metastatic and
androgen-dependent (AD) LNCaP and AI C4-2B,
DU145 and PC3 prostate cancer cells in vitro and in
vivo, without any toxic effect on normal prostate epithe-
lial cells (PrECs) [7,51,103-109,141]. More specifically,
curcumin may mediate growth inhibitory and apoptotic
effects in AD and AI prostate cancer cells by down-reg-
ulating the expression and/or activity of diverse onco-
genic and survival signalingc o m p o n e n t s ,i n c l u d i n g
EGFR, erbB2, hedgehog, androgen receptor (AR) and
PI3K/Akt, NF-B, Bcl-2, Bcl-xL and TMPRSS2-ERG
fusion protein (Figures 1 and 2) [107,108]. Curcumin
can also cause DNA damage and apoptotic/necrotic
death of prostate cancer cells by up-regulating diverse
pro-apoptotic factors such as the p53 tumor suppressor
protein, Bax, Bak, Noxa, p53 up-regulated modulator of
apoptosis (PUMA) and/or BCL-2-like 11 (Bim)
[107,108]. For instance, it has been reported that curcu-
min inhibited the growth and triggered the apoptosis of
AD LNCaP and AI PC3 cells in vitro by down-regulat-
ing the expression levels and intrinsic activities of EGFR
and its downstream signaling elements, including PI3K/
Akt and NF-B (Figures 1 and 2) [141,142]. Moreover,
curcumin effectively inhibited the SHH hedgehog
ligand-stimulated growth of the mouse prostate cancer
cell line derived from transgenic adenocarcinoma of the
mouse prostate (TRAMP) designated as TRAMP-C2,
LNCaP and PC3 cells at least in part, by inhibiting the
hedgehog cascade and GLI-1 expression [51]. Addition-
ally, it has also been reported that the treatment of PC3
cells with curcumin in vitro reduced the expression level
and activity of CC motif ligand 2 (CCL2) and MMP-9
proteolytic activity, thereby suppressing the cell adhe-
sion, motility and invasion [109].
Of particular interest, a combination of low doses of
curcumin and other dietary phytochemicals or antican-
cer drugs also induced greater anticarcinogenic effects
on prostate cancer cells than individual agents [51,52].
For instance, a treatment of 8-week old TRAMP mice
with a diet supplemented with 2% curcumin or 0.05% b-
phenyethylisothiocyanate (PEITC), or a combination of
1% curcumin plus 0.025% PEITC for a period of 10 or
16 weeks significantly inhibited the incidence of the for-
mation of high-grade prostatic intraepithelial neoplasias
and prostate cancer development, at least in part, by
down-regulating the Akt pathway [51,52]. The
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curcumin plus 2.5 μmol PEITC was also more effective
t h a nah i g h e rd o s eo f6μmol curcumin or 5 μmol
PEITC alone at inhibiting the tumor growth of PC3 cell
xenografts in immunodeficient mice by inhibiting Akt
and NF-B [51,52]. Moreover, curcumin also sensitized
LNCaP and PC3 cells in vitro and LNCaP xenografts to
tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis by up-regulating TRAIL-R1
and R2 (DR4 and DR5), Bax, Bak, p21
WAF1 and p27
KIP1
and down-regulating pAkt-induced NF-Ba n di t st a r -
geted gene products such as cyclin D1, vascular
endothelial growth factor (VEGF), urokinase-like plasmi-
nogen activator (uPA), MMP-2 and MMP-9 [143-145].
More specifically, a combination of curcumin (30 mg/
kg, three days per week) administered by oral injection
plus TRAIL (15 mg/kg, four times during first three
weeks) administrated by intravenous injection resulted
in greater tumor growth inhibitory and anti-angiogenic
effects on LNCaP cells subcutaneously implanted in
nude mice as compared to individual agents [143-145].
Together, these data support the therapeutic interest
of using curcumin or its derivatives, alone or in combi-
nation with other dietary substances, to improve the
efficacy of the current anti-hormonal and chemothera-
peutic treatments against locally advanced, hormone-
refractory and metastatic prostate cancers.
Pancreatic cancer
Pancreatic cancer is a highly lethal disease with a poor
long-term overall five-year survival rate of less than 5%
for patients diagnosed with locally advanced and meta-
static disease stages [146-148]. The poor prognosis of
patients is in part due to the early occurrence of meta-
static spread and the development of intrinsic and
acquired resistance by cancer cells during drug treat-
ment [146,147,149,150]. This lack of efficacy of the cur-
rent clinical therapies by surgical resection, radiotherapy
and/or gemcitabine-based chemotherapies against
aggressive and metastatic pancreatic cancers underlines
the urgent need to validate novel therapeutic agents for
overcoming treatment resistance. Importantly, curcumin
has been shown to induce the anti-proliferative, apopto-
tic, anti-angiogenic and chemosensibilizing effects on
diverse pancreatic cancer cells in vitro and in vivo
[27,69,70,151-159]. The anticarcinogenic effects of cur-
cumin were mediated through the down-regulation of
the expression and/or activity of distinct signaling ele-
ments, including EGFR, STAT-3, NF-B and its targeted
genes, multidrug transporters such as multidrug resis-
tance-associated protein 5 (MRP5), and modulation of
the expression levels of different micro RNAs
[27,69,70,151-159]. For instance, curcumin inhibited the
proliferation of Panc28 and L3.6pL pancreatic cancer
cells in vitro by down-regulating NF-kB-dependent gene
transactivation and Sp1, Sp2 and Sp3 transcription fac-
tors, which are overexpressed in pancreatic cancers
[153]. The intraperitoneal injection of curcumin in corn
oil (100 mg/kg/day, each 2
nd day for 18 days) also sup-
pressed the tumor growth of L3.6pL cell xenografted in
nude mice [153]. Moreover, curcumin potentiated the
anti-proliferative and apoptotic effects induced by gem-
citabine, a first-line chemotherapeutic drug, on BxPC-3,
Panc-1 and MiaPaCa-2 pancreatic cancer cell lines in
vitro [27,154]. A combination of curcumin (1 g/kg, once
daily), administered orally plus an intraperitoneal injec-
tion of gemcitabine (25 mg/kg, twice weekly) was more
effective than single agents at inducing the tumor
growth inhibitory and anti-angiogenic effects in a pan-
creatic tumor model derived from MiaPaCa-2 pancreatic
cancer cells orthotopically implanted in nude mice
[27,154]. The chemosensibilizing effects of curcumin
were mediated at least in part via the inhibition of
STAT-3 and NF-kB-regulated gene products such as
cyclin D1, c-Myc, Bcl-2, Bcl-xL, cellular IAP-1, COX-2,
MMPs and VEGF in pancreatic cancer cells (Figures 1
and 2) [27,154]. Of particular interest, it has also been
observed that a combination of low doses of curcumin
and other dietary agents (isoflavone, resveratrol and epi-
gallocatechin-3-galate), COX-2 inhibitor (celecoxib) or
an omega-3 fatty acid (docosahexaenoic acid) induced
synergistic growth inhibitory and apoptotic effects on
pancreatic cancer cells in vitro and in vivo [160-162].
Together, these data support the therapeutic interest
of using low doses of curcumin or its derivatives in
combination therapy with other cytotoxic agents acting
on multiple molecular targets as chemopreventive treat-
ment in the diet or to improve the efficacy of the cur-
rent gemcitabine-based chemotherapeutic regimens
against locally advanced, metastatic and recurrent pan-
creatic cancers.
Colorectal cancer
The loss of function by inactivating mutations in the
adenomatous polyposis coli (APC) or axis inhibition pro-
tein (axin) tumor suppressor proteins or activating
mutations in b-catenin concomitant with the activation
of the Wnt signaling pathway and nuclear accumulation
of b-catenin frequently occurs during gastrointestinal
cancers, including colorectal cancer initiation and pro-
gression, and leads to an enhanced expression of diverse
oncogenic products (Figures 1 and 2) [163-165]. More-
over, the activation of several tumorigenic signaling ele-
ments, such as EGFR, erbB2, mucin 1, Ras, PKC-bII and
orphan nuclear receptor peroxisome proliferator-activa-
tor receptor-g (PPAR-g), can promote the release of b-
catenin from the adherens junction complexes with E-
cadherin and/or its nuclear translocation (Figure 1)
[163,166]. Thus, the association of nuclear b-catenin
with the T cell factor (TCF)/lymphoid enhancer factor
Mimeault and Batra Chinese Medicine 2011, 6:31
http://www.cmjournal.org/content/6/1/31
Page 7 of 19(LEF) family of transcription factors may up-regulate the
expression of several gene products such as c-Myc,
cyclin D1, gastrin, COX-2, MMP-7, uPA receptor, CD44
and P-glycoprotein that are involved in colorectal cancer
development and treatment resistance (Figure 2) [163].
Importantly, it has been reported that the administration
of 0.6% curcumin in the diet prevented the progression
of colorectal cancer associated with colitis in C57BL/6
mice by inhibiting the translocation of b-catenin from
adherens junction complexes to the cytoplasm and
nucleus and reducing the levels of diverse proinflamma-
tory cytokines, inducible nitric oxide synthase (iNOS)
and COX-2 as compared to untreated mice (Figure 1)
[167]. Moreover, the administration of 0.2% or 0.5% cur-
cumin in the diet, approximately equal to 300 and 750
mg/kg curcumin per day respectively, commencing one
week postweaning in APC
-/+ mice, also reduced the inci-
dence of adenocarcinoma formation as compared to
untreated APC
-/+ mice [2,54]. In the same manner, a
treatment with curcumin (250 mg/kg body weight),
alone or in combination with dasatinib (10 mg/kg body
weight), for five consecutive days a week for 4 weeks,
was also effective at inducing tumor regression in a
familial APC
-/+mouse model as compared to untreated
APC
-/+ mice [2,54]. Additionally, curcumin was effective
at inhibiting tumor growth, invasion and in vivo metas-
tasis of human RKO and HCT-116 colon cancer cells
(wild-type p53
+/+) in the chicken-embryo-metastasis
a s s a yi np a r tb yd o w n - r e g u l a t i n gt h et r a n s c r i p t i o n a l
expression of micro RNA-21 and up-regulating the pro-
grammed cell death protein-4 (PDCD4), which is a tar-
get of micro RNA-21 [168].
In addition, curcumin has also been reported to cause
p53- and p21-independent G2/M phase arrest, caspase-
3-mediated cleavage of b-catenin, decreased transactiva-
tion of gene products such as c-Myc induced by b-cate-
nin/TCF/LEF complex, and an enhanced rate of
apoptosis in HCT-116 (p53
+/+), HCT-116 (p53
-/-)a n d
HCT-116 (p21
-/-) colon cancer cell lines (Figure 1)
[169]. A combination of curcumin with another dietary
resveratrol, pan-erbB inhibitor (EGF-R related protein,
ERRP), Src inhibitor dasatinib, 5-fluorouracil and/or
oxaliplatin also induced greater anti-proliferative, anti-
invasive and/or apoptotic effects on diverse colorectal
cancer cell lines than individual drugs in vitro and in
vivo [2,170-172]. The therapeutic effects of these combi-
nation therapies were mediated through a reduction of
the activated EGFR, erbB2, IGF-1R and Src phosphory-
lated forms and decreased expression levels and activ-
ities of extracellular signal-regulated kinases (ERKs),
pAkt, NF-B, Bcl-xL and/or COX-2 and caspase activa-
tion (Figures 1 and 2) [2,171,172]. For instance, it has
been observed that a combination of curcumin with the
current chemotherapeutic drugs, namely 5-fluorouracil
and/or oxaliplatin used for treating patients with
advanced colorectal cancer, synergistically inhibited the
growth of colon cancer cells in vitro [172]. A combina-
tion of curcumin plus diverse chemotherapeutic drugs
such as cisplatin, doxorubicin, danorubicin and vinscri-
tin was also accompanied by an enhanced intracellular
accumulation and improved cytotoxic effects of drugs
on colorectal cancer cells [173]. Importantly, a com-
bined treatment of curcumin given orally (1 g/kg once
daily) with capecitabine given by gavage (60 mg/kg
twice weekly) was also more effective than single agents
at inhibiting tumor growth, angiogenesis and metastases
at ascites and distant tissues such as the liver, intestine,
lung, rectum and spleen of HCT-116 colon cancer cells
orthotopically implanted in nude mice [116]. The sensi-
bilizing effects of curcumin on the antitumoral and anti-
metastatic properties of capecitabine were mediated
through a decreased expression of NF-kB-regulated gene
products such as c-Myc, Bcl-2, Bcl-xL, cIAP-1, COX-2,
intercellular adhesion molecule 1 (ICAM-1), MMP-9,
CXC chemokine receptor 4 (CXCR4) and VEGF (Figure
2) [116].
Thus, it appears that curcumin and its derivatives are
promising agents to target Wnt/b-catenin and NF-kB in
colorectal cancer cells, thereby counteracting cancer
initiation and progression and improving the efficacy of
the current chemotherapeutic treatments. Consistent
with this, the results from some recent investigations
have revealed that curcumin and its derivatives are also
effective at inducing the cytotoxic effects on chemoresis-
tant cancer cells, including cancer stem/progenitor cells
from colorectal cancer cell lines and other cancer cell
types.
Cytotoxic effects of curcumin on cancer stem/progenitor
cells
A growing body of experimental evidence has revealed
that self-renewing and tumorigenic cancer stem/pro-
genitor cells endowed with stem cell-like properties, also
designated as cancer- and metastasis-initiating cells, can
provide critical functions for cancer initiation and pro-
gression, treatment resistance and disease recurrence
[4,174]. Of great therapeutic interest, curcumin has been
reported to inhibit the clonogenecity and induce the
anti-proliferative and apoptotic effects on drug-resistant
and sphere-forming cancer cells expressing stem cell-
like markers as well as reverse the chemoresistance and
improve the cytotoxic effects induced by diverse che-
motherapeutic drugs on these immature cancer cells
[59-61]. For instance, curcumin, alone or in combination
with piperine, inhibited the mammosphere formation
and decreased the number of aldehyde dehydrogenase-
expressing cells detected in non-malignant and malig-
nant MCF-7 and SUM159 breast cells through the inhi-
bition of Wnt signaling cascade [59]. This suggests the
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chemopreventive agent for breast cancer. Moreover, the
treatment of HCT-116 or HT-29 colon cancer cells with
5-fluorouracil and oxaliplatin also resulted in an enrich-
ment of cancer cells with stem cell-like phenotypes as
evidenced by an increased proportion of cancer cell
fractions expressing high levels of CD133, CD44, CD166
and/or EGFR levels [60]. By contrast, curcumin, alone
or in combination with 5-fluorouracil and oxaliplatin,
induced a marked reduction in cancer stem cell-like
cells, as indicated by a decrease in the expression levels
of CD133, CD44, CD166 and EGFR as well as their abil-
ity to impair the colonosphere formation in vitro of che-
mosurviving HCT-116 or HT-29 colon cancer cells [60].
On the other hand, among the other methods fre-
quently used for the enrichment of a small population
of cancer stem/progenitor cells from cancer cell lines,
there is the Hoechst dye efflux technique that is particu-
larly useful when the stem cell-like markers are not
well-established [1,175,176]. In fact, the analysis of the
total cancer cell mass by Hoechst 33342 dye efflux tech-
nique can detect a small fraction of cancer cells with
stem cell-like properties designated as a side population
(SP) that possesses a higher ability to actively efflux the
fluorescent DNA-binding dye, Hoechst 33342 than the
non-SP cell fraction due to its elevated expression levels
of ATP-binding cassette (ABC) multidrug efflux pumps
[1,175,176]. In the regard, numerous studies have
revealed that the SP cell fraction detected in various
cancer cell lines, including leukemia, brain cancer, mela-
noma and epithelial cancers possesses the stem cell-like
properties [1,175,176]. Curcumin and its major metabo-
lite, namely tetrahydrocurcumin, have also been
reported to down-regulate the expression and/or activity
of multiple ABC multidrug transporters, including
ABCG2, multidrug resistance 1 (MDR-1) encoding P-
glycoprotein (ABCB1) and multidrug resistance protein-
1 (MRP-1; ABCC1) in parental cancer cell lines and
their derivatives that are resistant to multiple drugs, the
SP cell fraction and patient leukemic cells in vitro and
in mice in vivo [61-68]. Thus, curcumin can improve
the bioavailability and intracellular accumulation of
diverse chemotherapeutic drugs, reverse the chemoresis-
tance and act in cooperation with the other drugs to
induce greater cytotoxic effects (Figures 1 and 2). For
instance, it has been reported that the treatment of rat
C6 glioma cells with curcumin for 3-10 days or during
the Hoechst 33342 dye exclusion assay, resulted in a sig-
nificant decrease in the number C6 glioma cells detected
in the SP cell fraction by flow cytometry, suggesting that
curcumin can inhibit multidrug resistance transporters
in stem cell-like glioma cells [61].
Additional studies are, however, required to corrobo-
rate these results on the cancer stem/progenitor cell
subpopulations isolated cancer cell lines and those
detected in the patients in clinical settings.
Clinical trials of curcumin
The results from phase I/II clinical trials including the
dose-escalation studies with pure curcumin or curcumin
extract have indicated that oral administration of this
dietary compound as single agent is generally well-toler-
ated, non- or little toxic and induced the chemopreven-
tive and chemotherapeutic effects on some types of
diseases and aggressive cancers [69,71-81]. More specifi-
cally, it has been reported that the administration of
curcumin as single agent at dose levels of up to 100-
8000 mg/day was associated with no discernible or only
minimal toxicity while a highest dose of 12,000 mg/day
was not acceptable to some patients because of the large
amount of the curcumin capsules necessary to reach
this high dose [69,71-74,76-81,177]. The potential toxi-
city and side effects that have been observed with the
use of curcumin as a single agent given orally to the
patients include mild diarrhea and nausea, headache,
rash and yellow stool [71-73,76,79]. Despite these clini-
cal data suggesting that oral curcumin as single agent is
little toxic, further studies using escalating dose levels of
curcumin on a greater number of patients are necessary
to confirm its tolerability and safety profile after long-
term use, and more particularly in combination thera-
pies with other drugs. In this regard, we are reporting
accumulating lines of evidence that have indicated the
feasibility and safety to use the curcumin, alone or in
combination with other chemotherapeutic agent, in can-
cer prevention and therapies.
Clinical investigations of the chemopreventive and
chemotherapeutic effects of curcumin
Recent studies have indicated that curcumin exhibits
chemopreventive and chemotherapeutic effects on some
patients with pre-malignant lesions or different cancers
including oral, breast, prostate, pancreatic and colorectal
cancers (Additional file 1) [71-73,76-81,177,178]. More
particularly, the data from a phase I dose-escalation
study performed with 25 patients at high risk of devel-
oping cancer or with precancerous lesions and consist-
ing of the administration of 500-12,000 mg/day of oral
curcumin for 3 months have indicated that curcumin
was well-tolerated, non-toxic at doses of 8000 mg or
lower and induced a histolological improvement of pre-
cancerous lesions in some patients [71]. A histolological
improvement has been observed in one patient with
recently resected bladder cancer, two patients with oral
leucoplakia, one patient with intestinal metaplasia of the
stomach, one patient with uterine cervical intraepithelial
neoplasm and two patients with Bowen’sd i s e a s e[ 7 1 ] .
Moreover, the results from a pilot study on 15 patients
with advanced colorectal cancer refractory to standard
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stable disease after treatment with 2200 mg daily of oral
curcuma extract equivalent to 180 mg of curcumin for
2-4 months [72]. The data from a phase II trial carried
out with 21 evaluable pancreatic cancer patients, which
consisted of a treatment with 8000 mg of curcumin by
month daily until disease progression, with restaging
every two months, have also indicated that curcumin
was detectable in the peripheral circulation under glu-
curonide and sulfate conjugate forms [77]. These results
suggest that a high rate of metabolic transformation and
poor tissue distribution of curcumin may occur in can-
cer patients. Although curcumin is highly metabolic
instable with poor bioavailability, two pancreatic cancer
patients showed clinical biological response to curcumin
according to Response Evaluation Criteria in Solid
Tumors Group (RECIST) [77,179]. More specifically,
one patient had ongoing stable disease for more than 18
months and another additional patient had a brief but
marked tumor regression (73%) while no toxicity was
observed [77].
Other clinical trials have also confirmed the safety and
feasibility to use curcumin in combination therapy with
current chemotherapeutic treatments (Additional file 1)
[81,177,178]. For instance, the results from a phase I/II
study on 21 patients with disease progression with gem-
citabine-based chemotherapy have indicated that the
median overall survival time of the patients after a treat-
ment with curcumin plus gemcitabine or gemcitabine/S-
1 combination was 161 days and 1-year survival rate of
19% (95% confidence interval) (Additional file 1) [81].
Despite no partial or complete response of pancreatic
cancer patients was noted in this study, five patients
showed a stable disease according to RECIST criteria
[81,179]. Moreover, the results from another study on
17 patients with advanced pancreatic cancer, who were
treated with a dose of 8000 mg of curcumin by month
daily plus gemcitabine, have indicated that the time to
tumor progression was 1-12 months (median 2 1/2),
and overall survival was 1-24 months (median 5) [178].
Among 11 evaluable patients in this study, one patient
had a partial response, four had stable disease and six
showed tumor progression [178]. In addition, the data
from a phase I trial of dose-escalating curcumin that
was given orally plus docetaxel administrated as intrave-
nous infusion, which was carried out on 14 patients
with advanced and metastatic breast cancer, have also
indicated that five patients showed a partial tumor
response and three patients had a stable disease with
this combination therapy according to RECIST criteria
(Additional file 1) [177,179]. The grades 3-4 hematologi-
cal toxicity such as neutropenia and leucopenia was
observed after docetaxel treatment in most patients in
this study including a grade 4 neutropenia with a dose-
limiting toxicity (DLT) as well as two grade 3 diarrhea
with DLTs in two patients, grade 1 mucositis of oral
cavity in three patients, grade 1 hand-foot syndrome in
two patients and dermatological and lymphatic toxicity
in four patients [177]. The observations of two DLTs,
including one grade 4 neutropenia and one grade 3 diar-
rhea at a dose of 8000 mg/day of curcumin, combined
with the poor acceptability of this high dose of curcu-
min (16 capsules/day) by two patients has led to define
the maximal tolerated dose (MTD) of the curcumin at
8000 mg/day for this combination therapy [177].
Additional clinical trials are however necessary to
more precisely establish the toxicity and antitumoral
effects induced by combined docetaxel plus curcumin
versus the docetaxel or curcumin alone in a greater
number of the locally advanced and metastatic breast
cancer patients. Based on these encouraging results,
phase I/II/III clinical trials are now ongoing to investi-
gate the antitumoral activity of curcumin, alone or in
combination with the current chemotherapeutic drugs,
in patients diagnosed with a variety of cancers, including
multiple myeloma and non-small cell lung, advanced
breast, pancreatic and colorectal cancers. Thus, the
results from these additional clinical trials with curcu-
min or its derivatives should confirm their pharmacody-
namic and pharmacokinetic profiles and therapeutic
efficacy, alone or in combination therapy, for treating
patients with a wide range of aggressive and recurrent
cancers.
Together, these observations indicate that curcumin is
generally well-tolerated and without major toxicity and
displays anticarcinogenic activity on different cancer cell
types and some cancer patients without secondary
effects on normal tissues. This natural dietary com-
pound, however, exhibits a poor absorption and meta-
bolic instability which may limit its delivery and
biological activity in the tumoral tissues when admini-
strated orally. In this regard, we discuss here novel stra-
tegies that have been elaborated to optimize the
formulations and mode of administration of curcumin
for improving its bioavailability, selective delivery to
tumoral tissues and anticarcinogenic effects in cancer
patients.
New strategies for improving the physical and metabolic
stability, bioavailability and antitumoral effects of
curcumin
Although free curcumin [1,7-bis(4-hydroxy-3-methoxy-
phenyl)-1,6-heptadiene-3,5-dione] (also designated as
diferuloylmethane, Figure 3) possesses multiple thera-
peutic effects, the major disadvantages associated with
its oral administration are its high physical and meta-
bolic instability and poor aqueous solubility at neutral
and basic pH values limiting its systemic bioavailability
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[77,78,180-182]. As mentioned previously, the data from
preclinical and clinical studies have indicated that curcu-
min displays chemopreventive and chemotherapeutic
effects and is safe even at high doses in animal models
and humans. In counterbalance, curcumin typically
exhibits a high metabolic instability, poor tissue distribu-
tion and systemic bioavailability. These chemical fea-
tures of curcumin limit its clinical applications to treat
gastrointestinal tract malignancies that are exposed to
unmetabolized and active forms of curcumin
[11,77,78,183,184]. The main reasons that may contri-
bute to the low plasma level, limited tissue distribution
and decreased therapeutic efficacy of curcumin are as
follows: (1) poor absorption in the gastrointestinal tract
across the gut, (2) extensive metabolism through oxida-
tion, reduction, glucuronidation and sulfation, yielding
less active metabolites, and (3) rapid elimination from
the body [78,181-185]. The major metabolic products of
curcumin detected in hepatocytes in suspension in vitro
as well as in vivo after curcumin treatment in rodent
and human comprise dihydrocurcumin, tetrahydrocur-
cumin, hexahydrocurcumin, hexahydrocurcuminol and
their glucuronide and sulfate conjugates [72,78,181,183].
Of great clinical interest, it has been observed that the
combination of 2000 mg/day curcumin with an inhibitor
of hepatic and intestinal glucuronidation, piperine (20
mg/kg) resulted in higher curcumin concentrations in
serum and substantially improved bioavailability of cur-
cumin in healthy human volunteers [186]. Moreover,
several synthetic analogs of curcumin have been
designed and shown to exhibit a greater metabolic stabi-
lity and biological activity than those of curcumin itself
and are without increased toxicity (Figure 3)
[7,32,82-88,185,187-212]. A variety of experimental stra-
tegies and carrier systems have also been developed to
improve the selective and sustained delivery of curcumin
into cancer cells. These strategies include the use of cur-
cumin phospholipid complexes, the inclusion of curcu-
min in liposomes/lipidic micelles or the curcumin
encapsulation in diverse polymeric nanoparticle-based
formulations which may be unconjugated or conjugated
to a ligand or antibody that specifically targets the can-
cer cell receptor or epitopes (Figure 1)
[24,89-101,213,214].
New synthetic analogs of curcumin
A potential strategy to enhance the anticarcinogenic effi-
cacy and overcome the high physical and metabolic
instability and poor bioavailability of curcumin may be
the use of the synthetic chemical analogs of this natural
dietary compound endowed with improved physico-
chemical and pharmacological properties. Structure-
activity studies based on the tautomeric forms of natu-
rally occurring curcumin have led to the development of
some synthetic analogs endowed with a better chemical
stability and showing more potent anti-inflammatory,
anti-oxidant, anti-carcinogenic and/or anti-angiogenic
effects on diverse human cancer cell lines than curcu-
min (Figure 3) [7,32,82-88,185,187-212,215,216]. For
instance, it has also been observed that the protection of
the 4-OH groups of curcumin through methylation
yielded a dimethoxycurcumin analog exhibiting an
enhanced metabolic stability in vitro and in vivo as well
as greater anti-proliferative and apoptotic effects on
HCT-116 colorectal cancer cells and anti-proliferative
activity on breast and prostate cancer cell lines as com-
pared to curcumin (Figure 3) [185,187]. Moreover,
another synthetic analog of curcumin with a pyrazole
ring mimicking the enol form of curcumin, designated
as compound 12, was three to four-folds more effective
than curcumin at inducing the anti-proliferative effects
and showed the anti-angiogenic and anti-androgenic
activities on breast and prostate cancer cell lines
[187,189,192,204].
In addition, other synthetic analogs of curcumin also
include FLLL11, FLLL12, FLLL32 and GO-Y030 (Figure
3), which are more potent than curcumin at inhibiting
the growth, migration and/or colony formation in soft
agar of melanoma cells, hepatocellular carcinoma cells
and breast, prostate, pancreatic and colorectal cancer
cell lines [196-198,201,205-207]. It has been reported
that the anticarcinogenic effects of these structural ana-
logs of curcumin were mediated, in part, via the down-
regulation of the expression levels and activities of
erbB2, Akt and STAT-3 phosphorylated forms
[196-198,205,206]. Importantly, a non-toxic fluorinated
curcumin analog, namely EF24, has also been reported
to display improved pharmacokinetic profile and bioa-
vailability and greater growth inhibitory and apoptotic
effects than those of curcumin on lung, breast and pros-
tate cancer cell lines in vitro and animal models in vivo
(Figure 3) [82,83,86-88,208]. Based on the observations
indicating that the transmembrane receptor, tissue fac-
tor (TF) for coagulation factor VIIa is aberrantly and
abundantly expressed on many cancer cells, a new deliv-
ery system has also been developed to specifically target
the TF-expressing cancer cells with the curcumin ana-
log, EF24 [209]. This drug delivery system consists of
using a complex EF24-linker-Phe-Phe-Arg-mk-factor
VIIa, which can associate with TF on the surface of can-
cer cells and release the cytotoxic agent in the cyto-
plasm after endocytosis. This EF24 deliver system was
more effective at causing a cell cycle arrest on human
RPMI-7951 melanoma cells and MDA-MB-231 breast
cancer cells than the free EF24 compound [209].
Another study on a series of curcumin analogs has led
to the design of a novel synthetic analog containing a
pentadieone moiety, designated as compound 23, which
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inhibitory activity on MCF-7 and MDA-MB-231 breast
cancer cells, and LNCaP and PC3 prostate cancer cell
lines while it showed no significant effect on the immor-
talized but non-malignant MCF-10A mammary epithe-
lial cell line (Figure 3) [187]. Interestingly, a novel non-
toxic curcumin analog, namely 5-bis (4-hydroxy-3-meth-
oxybenzylidene)-N-methyl-4-piperidine (PAC), also
exhibited higher water solubility and stability in blood
and greater biodistribution and bioavailability than cur-
cumin [210]. PCA also displayed higher efficiency than
curcumin at inducing apoptosis on ER-a negative-
MDA-MB-231 breast cancer cells and antitumoral effect
on MDA-MB-231 cell xenografts in vivo by inhibiting
p21
WAP1, survivin and NF-B and its downstream effec-
tors, including cyclin D1 and Bcl-2, and activating cas-
pase cascade [210]. Another potent isozazole analog of
curcumin was also effective at inducing the cytotoxic
effects on hormone-dependent and ER-a expressing
MCF-7 breast cancer cells and hormone-independent
and multidrug resistant MCF-7R variant which lacks
aromatase and ER-a [55].
On the other hand, various chemical analogs of curcu-
min, including ASC-J9 and its derivatives, have been
shown to inhibit prostate cancer cell proliferation by
enhancing AR degradation or by acting as the pure AR
antagonist [84,204,211]. For instance, the characteriza-
tion of a series of curcumin analogs, which can function
as a 17a-substituted dihydrotestosterone (DHT), has
indicated that these compounds display potent anti-
androgenic activities superior to current clinical anti-
androgenic drug, hydroxyflutamide on AI PC3 and
DU145 cells transfected with wild-type AR or mutant
LNCaP AR and ARA70 co-activator respectively [204].
Moreover, a chemical hybrid molecule with two bulky
side chains, designated as compound 6, which has been
derived by a combination of curcumin and b-ionone
backbone, was also effective at inhibiting the wild-type
or mutant AR activity and induce the cytotoxic effects
on AD and AI prostate cancer cell lines in vitro [211].
More recently, some chemically stable curcumin deri-
vatives have also been shown to be more effective than
free curcumin for eradicating chemoresistant cancer
cells with the stem cell-like features from diverse cancer
cell lines. For instance, the difluorinated analog of cur-
cumin, 3,4-difluoro-benzo-curcumin, designated as CDF,
alone or in combination with 5-fluorouracil and oxali-
platin, was more potent than curcumin at reducing the
number of chemoresistant HCT-116 and HT-29 colon
cancer cells expressing CD44 and CD166 stem cell-like
markers as well as inhibiting the growth and inducing
the apoptosis and disintegration of colonospheres in
vitro (Figure 3) [212]. The anticarcinogenic effects of
this difluorinated curcumin analog were mediated
through the down-regulation of the expression and/or
activity of EGFR, IGF-1R, NF-B, c-Myc, b-catenin,
COX-2 and Bcl-xL signaling components and ABCG2
multidrug transporter combined with an activation of
the mitochondrial pro-apoptotic factor Bax [212]. In
addition, this difluorinated curcumin analog or CDF was
more effective than curcumin at inhibiting the sphere-
forming ability and increasing pancreatosphere disinte-
gration of parental and gemcitabine-resistant AsPC-1
and MIAPaCa-2 pancreatic cancer cells in vitro [216]. A
combination of CDF plus gemcitabine also induced
greater tumor growth inhibitory effects on MiaPaCa-2-
derived subcutaneous xenografts in severe combined
immunodeficient (SCID) mice than curcumin plus gem-
citabine through the down-regulation of the NF-B
activity, COX-2 and miR-21 expression and increased
expression of phosphatase tensin homolog deleted on
chromosome 10 (PTEN) and miR-200 expression [216].
Together, these data suggest that this difluorinated
curcumin analog or CDF may be effective at eradicating
the total colon or pancreatic cancer cell mass including
drug-resistant cancer cells with stem cell-like properties.
Novel nanotechnologies and delivery systems of curcumin
Diverse curcumin formulations have been developed
with different nanotechnologies consisting of its encap-
sulation or conjugation with nanoparticles, polymeric
micelles or liposomes to improve its stability, bioavail-
ability and specific and sustained delivery into cancer
cells and, consequently, its anticarcinogenic effects (Fig-
ure 1) [24,89-101,213,214]. For instance, it has been
shown that the curcumin encapsulation in biodegradable
and biocompatible poly(lactic-co-glycolic acid) (PLGA)
nanospheres resulted in an enhanced intracellular
uptake of curcumin-loaded polymeric nanospheres and
improved cytotoxic effects of curcumin on metastatic
LNCaP, PC3 and DU145 prostate cancer cell lines in
vitro relative to free curcumin, via the inhibition of NF-
B activity [24,91,94]. Similarly, a PLGA nanoparticle
formulation of curcumin conjugated with a monoclonal
antibody specific for ovarian cancer cells also sensibi-
lized the cisplatin-resistant A2780CP ovarian cancer
cells to the anti-proliferative and cytotoxic effects
induced by cisplatin or radiation via the down-regula-
tion of the expression of b-catenin, Bcl-xL and Mcl-1
pro-survival proteins [95]. The complexation of poly-b-
cyclodextrin (PCD) and curcumin was also effective at
improving the intracellular uptake of curcumin into C4-
2, DU145 and PC3 prostate cancer cells and its cyto-
toxic effects on these cancer cells as compared to free
curcumin [93]. Moreover, the cyclodextrin-curcumin
complex formulation was more effective than the free
curcumin at blocking NF-B-induced gene expression
such as cyclin D1, MMP-9 and VEGF, mediating the
anti-inflammatory and anti-proliferative effects on
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kemia cells [96]. Moreover, the loading of curcumin into
the copolymeric micelles of poly(ethylene oxide)-b-poly
(epsilon-caprolactone) (PEO-PCL) has also been shown
to be an effective strategy to enhance its solubility,
metabolic stability and delivery in diverse cancer cells
[92].
In addition, novel curcumin formulations have also
been shown to improve the therapeutic effects induced
by different chemotherapeutic drugs. For instance, the
systemic administration of gemcitabine plus polymeric
micelle-encapsulated curcumin formulation displaying
higher bioavailability in plasma and tissues as compared
to free curcumin, induced greater tumor growth inhibi-
tory and antimetastatic effects than curcumin on pan-
creatic cancer cells subcutaneously or orthotopically
implanted in nude mice via an inhibition of NF-kB and
its targeted genes [101]. Moreover, the co-administra-
tion by oral gavage of liposomal forms of curcumin or
resveratrol, prepared by mixing the phytochemical with
the liposomal lipid 1, 2-dimyristoyl-rac-glycero-3-phos-
phocholine, cooperatively reduced the incidence of pro-
static adenocarcinoma development in prostate-specific
PTEN knockout mice as compared to a single liposomal
curcumin or resveratrol formulation [89]. It has also
been shown that curcumin or resveratrol, alone or in
combination, induced the growth inhibitory and apopto-
tic effects on PTEN-CaP8 prostate cancer cells derived
from PTEN-knockout mice model of PC by the down-
regulation of the expression levels of pAkt, cyclin D1,
the mammalian target of rapamycin (mTOR) and AR
proteins [89].
Hence, the use of these novel chemical analogs and
nanotechnology-based formulations of curcumin repre-
sents a potential alternative strategy of great clinical
interest for overcoming the high metabolic instability
and poor bioavailability of curcumin, which are among
the principal factors limiting its therapeutic effects when
administrated orally.
Concluding remarks
Taken together, these studies carried out in the last ten
years have indicated that curcumin may act on multiple
oncogenic targets frequently deregulated in cancer cells,
including cancer stem/progenitor cells with stem cell-
like properties, during the progression of most human
aggressive cancers. Despite great interest in using the
curcumin as chemopreventive or therapeutic agent, its
high metabolic instability and poor systemic bioavailabil-
ity constitute the major obstacles to its applications in
human. Of clinical importance, recent studies have led
to the development and validation of novel curcumin
formulations with improved pharmacodynamic and
pharmacokinetic properties and anticarcinogenic efficacy
that offer great promise for overcoming treatment resis-
tance and curing cancer patients at different stages of
disease progression. Especially, these novel curcumin
formulations could be used to simultaneously target dif-
ferent tumorigenic cascades initiated by different growth
factors such as EGFR family members, hedgehog, Wnt/
b-catenin and their downstream signaling elements such
as PI3K/Akt and NF-B as well as multidrug resistance
transporters that may cooperate for the acquisition of
an aggressive behavior by cancer cells during disease
progression, treatment resistance and disease relapse.
Selective delivery of curcumin or its synthetic analogs
to tumors, alone or in combination with other antican-
cer drugs, may improve their chemopreventive and che-
motherapeutic efficacies against cancer progression and
relapse. Novel curcumin formulations may also be used
to reverse drug resistance, eradicate the total cancer cell
mass and improve the anticarcinogenic efficacy of the
current anti-hormonal and chemotherapeutic treatments
for patients with various cancers.
Additional structure-activity relationship studies of
curcumin and characterization of the pharmacokinetic
and anticarcinogenic proprieties of novelty identified
synthetic analogs and nanotechnology-based formula-
tions of curcumin, however, are essential to optimize
their physicochemical and anticancer properties and
selective delivery to tumor before they can be safely
used in the clinics. More particularly, the selective tar-
geting of nanoparticle-encapsulated curcumin formula-
tions to tumors could be further improved by their
conjugation to ligand or monoclonal antibodies (Figure
1). Future pre-clinical studies are also required to more
precisely establish the mechanisms of absorption, distri-
bution, mode of action and antitumoral, anti-metastatic
and chemosensibilizing effects of curcumin and its deri-
vatives on diverse animal models in vivo. Particularly, it
will be important to determine the therapeutic benefit
and chemosensibilizing effects of combining low doses
of curcumin and its derivatives with other nutraceuticals
and/or chemotherapeutic drugs used in the clinics.
Furthermore, the results from randomized, double blind
and placebo-controlled clinical trials carried out with
more cancer patients and after a long-term treatment
with curcumin and its derivatives, alone or in combina-
tion with the current therapies, are also necessary to
confirm their bioavailability, chemopreventive and thera-
peutic effects, drug interactions and potential synergy of
action on distinct cancer subtypes.
Thus, these future investigations should lead to more
chemically stable and effective curcumin formulations
that could be used as dietary substances, in safe condi-
tions for cancer prevention. These therapeutic agents
also could be used, alone or in combination with cur-
rent cancer therapies, for treating the patients diagnosed
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Page 13 of 19at the early and late stages with diverse types of aggres-
sive and recurrent cancers, and thereby prevent disease
relapse and the death of cancer patients.
Additional material
Additional file 1: Clinical trials on the evaluation of the safety, and
chemopreventive and chemotherapeutic effects of curcumin alone
or in combination therapy. Clinical trial data on the safety,
chemopreventive and chemotherapeutic effects of curcumin alone or in
combination therapy.
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